Immune cells from tumors show promise in advanced cancer trial
NCT ID NCT05417750
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This early-stage trial tested a therapy made from a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced solid tumors like melanoma, cervical cancer, and lung cancer. 43 adults participated to find the safest dose and check for side effects. The goal was to control the disease, not cure it, and patients may need ongoing monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100039, China
Conditions
Explore the condition pages connected to this study.